Literature DB >> 15305376

alphaV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma.

Pekka Koistinen1, Matti Ahonen, Veli-Matti Kähäri, Jyrki Heino.   

Abstract

The expression of integrin alphaV subunit on 4 melanoma-derived cell lines (A2058, SK-mel-5, WM-115 and WM-266-4) was analyzed. WM-115 cells, which originate from a primary tumor, were negative, whereas all 3 metastasis-derived lines had high levels of alphaV. To study alphaV integrins in the survival of melanoma cells, we developed a novel strategy that is exempt from extracellular inhibitors of ligand binding, which can activate integrin signaling and have integrin-independent effects on apoptosis. A recombinant adenovirus was used to transfer cDNA coding for a single-chain intracellular anti-alphaV integrin antibody into the melanoma cells. Anti-alphaV integrin adenovirus effectively inhibited the cell surface expression of alphaV integrins. In cell culture experiments, the depletion of alphaV integrins detached cells from extracellular matrix and induced apoptosis. Moreover, it prevented WM-266-4 cells from forming tumors in severe combined immunodeficiency mice but it could not prevent the growth of tumors that were formed by alphaV-negative WM-115 cells. Our results indicate that in primary melanomas there are cells that survive without alphaV integrins, whereas during the progression of disease cells can develop a dependency on these receptors. Furthermore, the data oppose the possibility that in melanoma cells apoptosis could occur due to direct activation of caspases by ligand-free alphaV integrins on the cell surface.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305376     DOI: 10.1002/ijc.20377

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

2.  A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma.

Authors:  Dana A M Mustafa; Lennard J Dekker; Christoph Stingl; Andreas Kremer; Marcel Stoop; Peter A E Sillevis Smitt; Johan M Kros; Theo M Luider
Journal:  Mol Cell Proteomics       Date:  2012-01-25       Impact factor: 5.911

3.  Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells.

Authors:  Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Bernd Niggemann; Kurt S Zänker; Thomas Dittmar
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Embryonic vasculogenesis in nodular melanomas and tumour differentiation.

Authors:  Bhanu Iyengar; Avantika V Singh
Journal:  Pathol Oncol Res       Date:  2011-01-04       Impact factor: 3.201

5.  Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.

Authors:  Petra Barros dos Santos; Juliana S Zanetti; Alfredo Ribeiro-Silva; Eduardo I C Beltrão
Journal:  Diagn Pathol       Date:  2012-08-16       Impact factor: 2.644

6.  Integrin trafficking and tumor progression.

Authors:  Sejeong Shin; Laura Wolgamott; Sang-Oh Yoon
Journal:  Int J Cell Biol       Date:  2011-10-30

7.  Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Authors:  Ingeborg M Bachmann; Rita G Ladstein; Oddbjørn Straume; George N Naumov; Lars A Akslen
Journal:  BMC Cancer       Date:  2008-12-05       Impact factor: 4.430

8.  Inhibitory Effects of PEI-RGD/125I-(αv) ASODN on Growth and Invasion of HepG2 Cells.

Authors:  Haidong Cai; Yu Qiao; Ming Sun; Xueyu Yuan; Qiong Luo; Yuehua Yang; Shidong Yuan; Zhongwei Lv
Journal:  Med Sci Monit       Date:  2015-08-10

Review 9.  Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.

Authors:  Thomas Böldicke
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

Review 10.  Specific in vivo knockdown of protein function by intrabodies.

Authors:  Andrea L J Marschall; Stefan Dübel; Thomas Böldicke
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.